Kang J, Irwin D, Chen-Plotkin A, Siderowf A, Caspell C, Coffey C, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner C, Singleton A, Toga A, Chowdhury S, Mollenhauer B, Trojanowski J, Shaw L, Lasch S, Flagg E, Poewe W, Sherer T, Meunier C, Rudolph A, Casaceli C, Seibyl J, Mendick S, Schuff N, Uribe L, Yankey J, Crawford K, Scutti A, Casalin P, Malferrari G, Hawkins K, Russell D, Leary L, Factor S, Sommerfeld B, Hogarth P, Pighetti E, Williams K, Standaert D, Guthrie S, Hauser R, Jankovic J, Hunter C, Stern M, Darin A, Leverenz J, Baca M, Frank S, Thomas C, Richard I, Deeley C, Rees L, Sprenger F, Oertel W, Willeke D, Shill H, Fernandez H, Mule J, Berg D, Gauss K, Galasko D, Fontaine D, Mari Z, McCoy A, Brooks D, Shah B, Barone P, Isaacson S, James A, Espay A, Espay K, Rowe D, Ranola M. Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. JAMA Neurology 2013, 70: 1277-1287. PMID: 23979011, PMCID: PMC4034348, DOI: 10.1001/jamaneurol.2013.3861.Peer-Reviewed Original Research